[go: up one dir, main page]

MX2017013874A - Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. - Google Patents

Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.

Info

Publication number
MX2017013874A
MX2017013874A MX2017013874A MX2017013874A MX2017013874A MX 2017013874 A MX2017013874 A MX 2017013874A MX 2017013874 A MX2017013874 A MX 2017013874A MX 2017013874 A MX2017013874 A MX 2017013874A MX 2017013874 A MX2017013874 A MX 2017013874A
Authority
MX
Mexico
Prior art keywords
pirazolopirimidinas
imidazopirazinas
receptor modulators
ampa receptor
formula
Prior art date
Application number
MX2017013874A
Other languages
English (en)
Other versions
MX373652B (es
Inventor
Devin M Swanson
M Savall Bradley
K Ameriks Michael
Wu Dongpei
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2017013874A publication Critical patent/MX2017013874A/es
Publication of MX373652B publication Critical patent/MX373652B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporcionan en la presente invención compuestos de la Fórmula (I) y sales, N-óxidos o solvatos farmacéuticamente aceptables de estos, (ver Fórmula) la presente invención proporciona, además, composiciones farmacéuticas, que comprenden compuestos de la Fórmula (I), y métodos para usar los compuestos de la Fórmula (I).
MX2017013874A 2015-04-29 2016-04-28 Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. MX373652B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154310P 2015-04-29 2015-04-29
PCT/US2016/029791 WO2016176457A1 (en) 2015-04-29 2016-04-28 Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators

Publications (2)

Publication Number Publication Date
MX2017013874A true MX2017013874A (es) 2018-06-22
MX373652B MX373652B (es) 2020-04-02

Family

ID=55919907

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013874A MX373652B (es) 2015-04-29 2016-04-28 Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.

Country Status (12)

Country Link
US (1) US10513523B2 (es)
EP (1) EP3288945B1 (es)
JP (1) JP6800885B2 (es)
KR (1) KR20170141768A (es)
CN (1) CN107567452B (es)
AU (1) AU2016255431B2 (es)
BR (1) BR112017023038A2 (es)
CA (1) CA2984307A1 (es)
ES (1) ES2759348T3 (es)
MX (1) MX373652B (es)
NZ (1) NZ736055A (es)
WO (1) WO2016176457A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018080916A1 (en) * 2016-10-26 2018-05-03 Janssen Pharmaceutica Nv Fused azaheterocyclic compounds and their use as ampa receptor modulators
CN107056789B (zh) * 2017-04-21 2019-03-29 陈剑 具有取代吡嗪并咪唑类衍生物,其制备及其在医药上的应用
US11447488B2 (en) 2017-10-06 2022-09-20 Takeda Pharmaceutical Company Limited Heterocyclic compounds
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
CN113272303B (zh) * 2018-11-30 2024-09-17 上海拓界生物医药科技有限公司 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用
WO2020249785A1 (en) * 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
WO2021115286A1 (zh) * 2019-12-10 2021-06-17 成都倍特药业股份有限公司 一种可用作shp2抑制剂的含氮杂原子的六元并五元芳环衍生物
US20230167140A1 (en) * 2020-04-30 2023-06-01 Shanghai Senhui Medicine Co., Ltd. Inositol derivative and use thereof
US20240216357A1 (en) * 2021-03-24 2024-07-04 Sichuan Huiyu Pharmaceutical Co., Ltd. Polycyclic compound and application thereof
CN116836167B (zh) * 2022-03-25 2025-09-09 腾讯科技（深圳）有限公司 咪唑并[1,2-a]吡嗪或吡唑并[1,5-a]嘧啶衍生物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
TW251284B (es) 1992-11-02 1995-07-11 Pfizer
AU685881B2 (en) 1994-02-10 1998-01-29 Pfizer Inc. 5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
WO2000001376A2 (en) 1998-07-02 2000-01-13 Eisai Co., Ltd Pharmaceutical compositions and their uses for treatment of demyelinating disorders
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
WO2002014294A2 (en) 2000-08-11 2002-02-21 Eli Lilly And Company Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function
PL1786812T3 (pl) 2004-09-03 2012-04-30 Merck Serono Sa Pirydynometylenoazolidynony i ich zastosowanie jako inhibitorów fosfoinozytydów
WO2007135529A2 (en) 2006-05-23 2007-11-29 Pfizer Products Inc. Azabenzimidazolyl compounds as mglur2 potentiators
EP2086643B1 (en) * 2006-11-03 2011-03-23 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
WO2008113795A1 (en) * 2007-03-20 2008-09-25 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
GB0711089D0 (en) * 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009067607A2 (en) * 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
AU2008333865A1 (en) * 2007-12-06 2009-06-11 Schering Corporation Gamma secretase modulators
WO2010005528A2 (en) 2008-06-30 2010-01-14 Ironwood Pharmaceuticals Incorporated Pyrrolopyridine carboxylic acid derivatives
GB0822425D0 (en) * 2008-12-09 2009-01-14 Glaxo Group Ltd Compounds
GB0822981D0 (en) * 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
EP2579717A4 (en) 2010-06-09 2013-12-11 Merck Sharp & Dohme POSITIVE ALLOSTERIC MODULATORS OF MGLUR2
EA022078B1 (ru) * 2010-08-10 2015-10-30 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение и его применение
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
JO3225B1 (ar) 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
EA201591360A1 (ru) 2013-02-19 2016-03-31 Пфайзер Инк. Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
ES2865330T3 (es) * 2015-04-29 2021-10-15 Janssen Pharmaceutica Nv Azabenzimidazoles y su uso como moduladores del receptor AMPA

Also Published As

Publication number Publication date
EP3288945A1 (en) 2018-03-07
MX373652B (es) 2020-04-02
CN107567452B (zh) 2020-07-07
WO2016176457A1 (en) 2016-11-03
ES2759348T3 (es) 2020-05-08
CA2984307A1 (en) 2016-11-03
BR112017023038A2 (pt) 2018-07-03
KR20170141768A (ko) 2017-12-26
AU2016255431B2 (en) 2020-05-07
CN107567452A (zh) 2018-01-09
AU2016255431A1 (en) 2017-10-26
JP2018514537A (ja) 2018-06-07
EP3288945B1 (en) 2019-09-18
US10513523B2 (en) 2019-12-24
US20180118751A1 (en) 2018-05-03
JP6800885B2 (ja) 2020-12-16
NZ736055A (en) 2023-05-26

Similar Documents

Publication Publication Date Title
CO2017011017A2 (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CR20150524A (es) Compuestos de heteroarilo y sus usos
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
CR20160374A (es) Ciclopentanos sustituidos en 1,2 como antagonistas del receptor de orexina
ECSP17069696A (es) Compuestos novedosos
CO2019004164A2 (es) Compuestos de piridina bicíclicos fusionados y su uso como moduladores de receptores ampa
MX2017000183A (es) Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
MX2016010524A (es) Derivados de piridazina para uso en la prevencion o tratamiento de trastorno ataxico.
CO2019004143A2 (es) Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
MX369806B (es) Compuestos de indolona y su uso como moduladores del receptor ampa.

Legal Events

Date Code Title Description
FG Grant or registration